http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0707671-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2007-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_724de11d9811d4bec84d71ecd10828ac |
| publicationDate | 2011-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0707671-A2 |
| titleOfInvention | anti-cancer pharmaceutical composition |
| abstract | ANTI-CANCER PHARMACEUTICAL COMPOSITION. An anti-cancer pharmaceutical composition for use in preventing or treating a carcinoma, sarcoma or hematopoietic cancer is described. The composition comprises a compound represented by the general formula (1) or a salt thereof as an active ingredient: (I) in which R represents a phenyl group substituted with 1 to 5 substituents selected from a halogen atom, a hydroxy group, a C ~ 1 ~ -C ~ 6 ~ -alkyl group, a C ~ 1 ~ -C ~ 6 ~ -alkyl halogen group, a C ~ 1 ~ -C ~ 6 ~ -alkoxy group, an amino group that may be substituted, a C ~ 3 ~ -C ~ 10 ~ -cycloalkyl group that can be substituted, a C ~ 1 ~ -C ~ 7 ~ -aliphatic acyl group, a 4- to 7-membered saturated heterocyclic group, an aromatic heterocyclic group from 5 to 6 nitrogenous members, a nitro group and a cyan group; and X represents an oxygen or sulfur atom. An anti-cancer pharmaceutical composition comprising an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor or a Raf kinase inhibitor and a composition represented by the general formula ( 1) above or a salt of the same as active ingredients. |
| priorityDate | 2006-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 262.